MCAM and prostate cancer: To determine whether high and low myosin IC isoform A expression correlated with distinct cell surface phenotypes, we extended our panel adding seven surface molecules (CD10, CD13, CD29, CD38, CD54, CD146, and CD166) that have been associated with the tumorigenic potential of prostate cancer cells [16–22].